Navigation Links
Intercell AG Announces Q3 2010 Results and Updates on R&D Progress and Management

VIENNA, Nov. 9, 2010 /PRNewswire-FirstCall/ -- Today, Intercell AG (VSE: ICLL) announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

Financial Results

  • IXIARO and JESPECT sales revenues continue showing significant year-on-year growth – sales revenues totaled EUR 9.4m in the 9 months ended September 30, 2010, compared to EUR 5.6m in the same period of the previous year.
  • Intercell's aggregate revenues decreased by 28.4% from EUR 29.5m in the 9 months ended September 30, 2009 to EUR 21.1m in the same period of 2010.
  • Net loss for the first nine months of 2010 increased to EUR 50.9m mainly driven by increased R&D expenses for late stage development programs and non-cash currency effects.
  • Solid cash position with EUR 107.1m.
  • Outlook full year 2010: Net loss for the full year 2010 expected to reach approximately EUR 40.0m, at the high end of previously communicated range, and this assumes positive outcome of upcoming milestone events.

  • Key Financial FiguresEUR in thousands

    3 months ended

    9 months ended

    Year endedSept 30,
    2010Sept 30,

    Sept 30,
    2010Sept 30,

    Dec 31,



    61,681Net profit/(loss)



    (18,375)Net operating cash flow



    (25,995)Cash and available-for-sale financial assets, end of period



    180,019IXIARO®/JESPECT®Intercell reports that the positive trend of increasing sales of IXIARO/JESPECT seen in Q2 2010 continued in Q3. Intercell's product is the only vaccine against Japanese Encephalitis licensed in Europe. It is manufactured for, and supplied into, the U.S., EU and Canada and the only vaccine being produced for the U.S. military. U.S. military sales in 2010 depend on further use of residual product stock of JE-Vax®. A significant increase in sales is possible for 2011, when leftover inventory of JE-Vax is expected to be exhausted or abandoned.

    The Department of Health, Government of the Hong Kong Special Administrative Regions has approved Intercell's vaccine to prevent Japanese Encephalitis. The licensure process has been initiated for additional territories, and further recommendations are expected also for other key countries in Europe. These recommendations are essential to continue advancing product awareness and market growth.

    The pediatric Phase III studies for IXIARO/JESPECT for use in children travelling to endemic areas are progressing according to plan, with data expected in 2012. These studies are the basis for a label extension to make the existing vaccine available for travelling children.

    Based on Intercell's technology a novel JE vaccine candidate is also being developed for the endemic markets, where the WHO recommends that Japanese Encephalitis vaccination be integrated into national immunization programs. Clinical development in endemic areas is progressing, with a pivotal Phase III trial in children scheduled to start by the end of 2010 / early 2011 sponsored and managed by Intercell's partner, Biological E., in India.

    Leading R&D portfolio in hospital infectionsA Phase II clinical trial involving IC43, the vaccine candidate against infections with the bacterium Pseudomonas aeruginosa, met primary immunogenicity and safety endpoints; a statistically significant reduction in mortality compared to placebo was observed for the non-adjuvanted vaccine group. If confirmed by pivotal clinical trials, this could make IC43 an important vaccine for ICU patients who are subject to a particularly high mortality risk associated with hospital-acquired infections. The vaccine generated a good immune response and was well tolerated. Vaccine-related serious side-effects which would raise any safety concern were not observed. The results provide a strong basis for evaluation of further development options. Intercell and its partner Novartis will determine next steps.

    Clostridium difficile program planned to enter clinic: After successful pre-clinical trials, Intercell is progressing its vaccine candidate to prevent infections with Clostridium difficile (C. diff). C. diff is the leading cause for nosocomial Diarrhea in Europe and the U.S. A Phase I clinical study is expected to start in 2010.

    Staphylococcus aureus vaccine (V710) on track: The Phase II/III study conducted and funded by Merck & Co., Inc. in cardiothoracic surgery patients for the investigational S. aureus vaccine is progressing to plan. The first critical interim analysis (surpassing futility) is expected in 2011.

    Good progress in development pipeline – programs progressing according to plan

  • Recruitment for the pivotal Phase III study of approximately 2,000 travelers for Intercell's investigational Travelers' Diarrhea (TD) Vaccine Patch is completed. The first data from that trial, conducted in travelers to Mexico and Guatemala, is expected for end 2010/early 2011. The enrollment of a complementary 800-traveler Phase II study in those travelling to India has also been completed; first data is expected in Q4 2010. The trial in India is the first study outside South America and has the potential to demonstrate proof of concept for the vaccine in Asia.
  • Intercell will pursue activities with GSK to prepare markets as soon as data on Phase II and Phase III trials becomes available. Diarrhea is the most common health problem among travelers from developed countries who visit developing areas and most of the diarrheal cases in travelers are caused by bacteria, primarily by ETEC strains (Escherichia coli).
  • Intercell and GSK will continue development of the investigational Vaccine Enhancement Patch (VEP) system for Avian H5N1 Influenza vaccination as part of a collaborative agreement signed in December 2009. The initiation of a respective clinical trial is expected for end 2010/early 2011.
  • Intercell and Romark joined forces in combining therapies against Hepatitis C. The companies are designing a treatment that combines Intercell's investigational Hepatitis C vaccine, IC41, with Romark's antiviral drug, nitazoxanide - a combination Phase II trial is expected to start in H1 2011.

  • Management Effective October 1, 2010, Staph Leavenworth Bakali joined Intercell's Management Board as Chief Business Officer, with key responsibilities for the commercial aspects of the Company, directly leading Marketing & Sales, Corporate & Business Development, and Alliance Management.

    The full report can be downloaded at

    This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


    SOURCE Intercell AG
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
    2. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
    3. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
    4. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
    5. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
    6. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
    7. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
    8. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
    9. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
    10. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
    11. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
    Post Your Comments:
    (Date:10/9/2015)... October 9, 2015 ... The report summarizes key statistics ... status of the manufacturers making it ... direction for companies and individuals interested ... . --> ...
    (Date:10/9/2015)... N.Y. , Oct. 9, 2015 ... world,s largest provider of health care products and services ... reminded its customers that the Henry Schein Disaster Relief ... experience operational, logistical or financial issues as a result ... . The toll-free number for all Henry ...
    (Date:10/9/2015)... 9, 2015   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical study of telotristat etiprate has been accepted for ... to be held from October 15-17, in Austin, ... who completed the randomized treatment portion of the TELESTAR study ... session. --> --> Telotristat ...
    Breaking Medicine Technology:
    ... , SARASOTA, Fla., Nov. 6 Roper Industries, ... it has signed a definitive agreement to acquire Verathon, ... The Verathon Board of Directors has approved the transaction ... and closing conditions, including shareholder approval. The parties ...
    ... Companies (ASMC), an informal working group of mid-market and ... 3962, the "Affordable Health Care for America Act," introduced ... fear that the cumulative effect of a host of ... bring new medicines to market. , From ...
    Cached Medicine Technology:
    (Date:10/9/2015)... ... 09, 2015 , ... Smoke alarms can save lives. In fact, according to ... dying in reported home fires in half. As part of Fire Prevention Week, ... installed and maintained. , Half of home fire deaths result from fires reported between ...
    (Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... offering a special promotion on Invisalign, the orthodontic system that uses clear, plastic ... aligners are almost invisible against the teeth, which allow patients to complete treatment ...
    (Date:10/9/2015)... ... October 09, 2015 , ... Matrix IT Medical Tracking ... for TRACTUS, the world’s first sterile field scanner. , The TRACTUS ... the FDA’s recent Unique Device Identifier (UDI) Final Rule, which will require manufacturers ...
    (Date:10/9/2015)... ... October 09, 2015 , ... The Asthma and Allergy Foundation of ... Disease Control and Prevention (CDC) to improve the knowledge and skills of underserved adults ... awarded a project by the CDC and allows AAFA to continue vital efforts to ...
    (Date:10/9/2015)... ... October 09, 2015 , ... Cambias Insurance ... surrounding communities, is initiating a combined charity effort with Animal Rescue New Orleans ... southern Louisiana. , Animal Rescue New Orleans is a non-profit organization committed ...
    Breaking Medicine News(10 mins):
    ... 2007 Ken,Sperling has been named senior vice ... this role, Sperling will lead the,development of products ... report directly to CIGNA HealthCare Senior Segment President ... and,employer-based programs serving the U.S. senior population. ...
    ... psoriasis at the age of 5; as a teenager, she,says ... her body.,Today, her curse is her cause, and she is ... 12 Team up with,CariDee English, Cycle 7 winner of ... in San Diego, Calif., Saturday, Sept.,29, at Mission Bay Park. ...
    ... Inc., a,pioneer in health and condition (disease) management, ... Synergy Personal Health,Management program at DMAA,s Disease Management ... at Caesar,s Palace in Las,Vegas. With the ... to stay,informed of the best practices, latest technologies ...
    ... N.J., Sept. 12 Hooper Holmes,Inc. (Amex: HH ... as,President of the Company,s new Health & Wellness Division. ... as Senior Vice President,and Business Development Officer, charged to ... including the wellness,market. The division has made rapid progress ...
    ... Deficit Hyperactivity Disorder (ADHD) is a prevailing issue in ... every year. A new study reveals that Pycnogenol, (pic-noj-en-all), ... French maritime pine tree, reduces ADHD in children. The ... and dopamine, resulting in a decrease of ADHD. ...
    ... NSERC Idea to Innovations grant and an Ontario Early ... and Nanosystems Laboratory ( ) at the University ... technology for automated microinjection of zebrafish embryos. , ... microrobotic system is capable of immobilizing a large number ...
    Cached Medicine News:
    ... Sensor Intravascular Mikro-Tip Pressure Catheters; Millar ... dual pressure sensor catheters for simultaneous ... are suitable for measuring pressure gradients ... across a vascular stenosis. The catheters ...
    ... the United States dying from Sudden Cardiac Death ... recommended that AEDs be used as a standard ... Any AED can provide a life-saving shock during ... continuous monitoring capabilities during and after resuscitation. Plus ...
    ... These catheters are indicated ... soft emboli and thrombi from ... These catheters may also be ... blood vessels, infusion of fluids, ...
    ... catheter is designed to remove thrombus ... saline jets travel backwards at half ... a low pressure zone causing a ... the catheter where it is fragmented ...
    Medicine Products: